Literature DB >> 8296673

Anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver disease.

A H Mulder1, G Horst, E B Haagsma, J H Kleibeuker, C G Kallenberg.   

Abstract

ANCA were detected in 67% of sera from patients with primary sclerosing cholangitis (n = 15), in 83% of sera from patients with autoimmune chronic active hepatitis (n = 18) and in 35% of sera from patients with primary biliary cirrhosis (n = 20). ANCA were not detected in non-autoimmune chronic liver diseases. Characterization studies of the antigens involved showed that ANCA in autoimmune liver disease are not directed against myeloperoxidase (mpo), proteinase 3 (pr3) or elastase (hle), but the ANCA in autoimmune liver disease show reactivity with lactoferrin, a 67/66 kD protein combination or a 63/54 kD protein combination on Western Blots.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8296673     DOI: 10.1007/978-1-4757-9182-2_99

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

1.  pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.

Authors:  L K Gordon; M Eggena; G N Holland; J M Weisz; J Braun
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

2.  Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study.

Authors:  E Röther; T Schochat; H H Peter
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

3.  Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.

Authors:  Troy D Jaskowski; Christine M Litwin; Harry R Hill
Journal:  Clin Vaccine Immunol       Date:  2006-06

4.  Liver disorders in inflammatory bowel disease.

Authors:  Victor Uko; Suraj Thangada; Kadakkal Radhakrishnan
Journal:  Gastroenterol Res Pract       Date:  2012-02-15       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.